| 0 | 💬 0 |
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.
(linkinghub.elsevier.com)
|
Cell Reports Medicine 2026-06-30 | #nsclc #brain-metastases #egfr-mutation #clinical trial #targeted therapy |